TKNO — Alpha Teknova, Inc.

Summary of Teknova's Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Revenue: $10.0 million, an 8% increase from $9.3 million in Q4 2024.
• Full Year 2025 Revenue: $40.5 million, a 7% increase from $37.7 million in 2024.
• Gross Profit: Q4 gross profit was $3.2 million (32.5% margin), up from $2.1 million (23.0% margin) in Q4 2024. Full year gross profit was $13.4 million (33.2% margin), up from $7.2 million (19.2% margin) in 2024.
• Net Loss: Q4 net loss was $4.8 million ($0.09 per share), improved from a loss of $5.7 million ($0.11 per share) in Q4 2024. Full year net loss was $17.3 million ($0.32 per share), down from $26.7 million ($0.57 per share) in 2024.
• Adjusted EBITDA: Negative $1.8 million in Q4 2025, an improvement from negative $3.2 million in Q4 2024. Full year adjusted EBITDA was negative $6.7 million, improved from negative $14.5 million in 2024.
• Free Cash Flow: Negative $9.8 million for the full year, better than the guidance of less than $12 million.

2. Strategic Updates and Business Highlights

• Customer Growth: Active clinical customers increased to 60, a 25% rise from 2024, with notable growth in therapies supported.
• Product Segments: Revenue from catalog products grew by low double digits; Clinical Solutions revenue rose 47% in Q4 2025.
• Operational Efficiency: Achieved 95% on-time delivery and improved manufacturing efficiencies contributed to better gross margins.
• Investment in Growth: Plans to invest $2 million annually in commercial capabilities to enhance market presence and accelerate revenue growth.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected total revenue of $42 million to $44 million, implying approximately 6% growth compared to 2025.
• Long-term Growth: Anticipated sustainable revenue growth of 20% to 25% over the longer term, with an adjusted EBITDA positive target by the end of 2027.
• Market Recovery: Positive indicators from biotech funding in Q4 2025 may lead to increased revenue in 2026, particularly in the custom biopharma segment.

4. Bad News, Challenges, or Points of Concern

• Declining Average Revenue per Customer: Average revenue per customer decreased due to the addition of new customers, particularly in early-stage therapies.
• Market Uncertainty: Cautious outlook for 2026 due to the need for sustained biotech funding and a lack of larger orders from Clinical Solutions customers.
• Operational Risks: High fixed costs associated with operations may lead to variability in revenue recognition and cash flow.

5. Notable Q&A Insights

• Emerging Markets: Discussion on growth potential in sequencing, spatial genomics, and cancer screening, with a focus on increasing commercial investments to capture these opportunities.
• Customer Transition: Clarification on the revenue step-up for customers transitioning from RUO to GMP, with significant increases expected as therapies progress through clinical phases.
• FDA Guidance Impact: Potential for shorter drug development timelines could benefit Teknova, especially if therapies supported by the company reach commercialization faster.
• Cell and Gene Therapy Revenue: 24% of total revenue in 2025 came from cell and gene therapy-related customers, consistent with 2024.

Overall, Teknova reported solid growth in 2025, with strategic investments aimed at enhancing future performance, although challenges remain in customer revenue dynamics and market conditions.